BioBlog-Weekly-Image-Humana-Building

Merck, Humana, Teva, and Government Health Regulations in the News

IP Blog | Innovation Partners | January 21, 2018

In this week’s Innovation Partners BioBlog, we share updates from companies such as Humana, Merck, and Teva. Humana has chosen to exit industry trade group AHIP, while Teva and Merck announce updates on important new drugs. This and more in this week’s Innovation Partners BioBlog. Congressional Advisory Group Supports Changes In Medicare Doctor Payments The […]

Read Full Post »


BioBlog-Post-Image-of-a-Nurse

Cancer Risks, Treatment, and Drugs in the News

IP Blog | Innovation Partners | January 14, 2018

This week’s Innovation Partners BioBlog spotlights cancer risks, treatment, and drugs in the news. A new study out of China that assessed nearly 4 million women working long-term night shifts found an increased risk of cancer. New medications are on the horizon, while the J.P. Morgan Healthcare Conference begins in San Francisco. This week’s headlines […]

Read Full Post »


BioBlog-Weekly-Post-Image-Skin-Cream

Cancer Care and Treatment in the Spotlight This Week

IP Blog | Innovation Partners | January 7, 2018

Cancer deaths have dropped to their lowest rate since 1991, mostly in part to fewer Americans smoking. This week’s BioBlog is filled with more good news from the world of oncology and cancer treatment, including advances in the treatment of breast cancer, renal cell carcinoma, squamous cell carcinoma, and brain tumors. FDA Clears Stereotactic Radiotherapy […]

Read Full Post »


BioBlog-weekly-post-image

A Look at the Top Health News Stories of 2017 and More

IP Blog | Innovation Partners | January 1, 2018

2017 was a year of many landmarks, including the highest NMEs approved in any year except 1996. It was a year of many milestones in the war on cancer and a year in which the contentious fight over healthcare, insurance, and who pays for it continued in Congress. A look at these and other top […]

Read Full Post »


Microscope-Image-For-Weekly-BioBlog

Cancer Care, Cost and Treatment News and More

IP Blog | Innovation Partners | December 24, 2017

This week’s BioBlog focuses on cancer care. There is a hidden costs of cancer care that affects small business owners who must often take time away from their businesses while they receive treatment. Cancer clinical trials often include the sickest patients, yet for these patients, it may be their last, best hope for a cure. […]

Read Full Post »


BioBlog weekly post image

All Eyes on Congress as the Tax Bill Deadline Draws Near; Tasty Pigs; and More

IP Blog | Innovation Partners | December 17, 2017

All eyes are on Congress as the Senate and House work out details on a tax bill due to President Trump by Christmas that provides sharp tax cuts to corporations and eliminates or reduces personal tax credits. Biotech is in the news, including a fascinating look at the top stories of 2017. CRISPR and tasty […]

Read Full Post »


bioblog-Image-Post

CVS Acquires Aetna in a Potentially Game-Changing Move plus Rating Oncologists, New Studies and More

IP Blog | Innovation Partners | December 10, 2017

This week, the top news story is CVS’ proposed merger with health insurer Aetna. The deal, which will cost the pharmacy chain $69B, puts it on a competitive playing field with United Healthcare and Optum, a pharmacy benefits management company, and sets up the chessboard against giant Amazon’s potential forays into healthcare. In addition to […]

Read Full Post »


Bio-Blog-Post-Photo

How Quickly Will Drug Prices Come Down: A Look at This Week in Healthcare

IP Blog | Innovation Partners | December 3, 2017

This week’s BioBlog focuses on the new: new studies on cancer care, physician reimbursement and more, as well as new venture capital initiatives from United Healthcare. Let’s not forget the potential of a new HHS secretary as confirmation hearings continue. A look at this week in healthcare in the Innovation Partners BioBlog. HHS secretary nominee […]

Read Full Post »


bio blog image

News, Updates, and Insights from the World of Healthcare

IP Blog | Innovation Partners | November 26, 2017

This week’s BioBlog features updates from the world of cancer therapies and pharmaceutical drugs, the potential impact of the loss of the Orphan Drug Tax Credit as an unintended consequence of the Affordable Care Act repeal, and much more. People Willing to Trade Treatment Efficacy for Reduced Side Effects in Cancer Therapies A study published […]

Read Full Post »


pills

Improving Quality of Patient Care While Decreasing Costs in the News This Week

IP Blog | Innovation Partners | November 16, 2017

Front and center in the news this week is both the proposition and the evidence that improving patient care while decreasing costs is possible. Humana offers a study showing how value-based care can improve quality and lower costs at the same time the Trump Administration pushes back against value-based care. Loxo sold Bayer the rights […]

Read Full Post »


Healthcare Marketplace Access News Innovation Partners

CMS Issues Final Rules, UnitedHealth’s Business Moves, and Much More

IP Blog | Innovation Partners | November 12, 2017

This week’s BioBlog takes a look at UnitedHealth’s business moves. While all eyes have been on Amazon, UnitedHealth is, in fact, taking up more market share. In addition to business news, we take a look at the new CMS final rules and their impact, as well as other important industry and business news for healthcare, […]

Read Full Post »


BioBlog-Medicine-Image

Oncology Care, Health Industry Updates and More in the News This Week

IP Blog | Innovation Partners | November 5, 2017

Oncology care takes front and center this week with reports from the CMS on patient care, support for approval of several biosimilar drugs, and a complimentary seminar from the FDA coming up on November 13th. This and more in this week’s Innovation Partners BioBlog. CMS’s Oncology Care Model Has Issues, But Participants Say Care Has […]

Read Full Post »


Researchers at Sloan Kettering working to find ways to help immune checkpoint inhibitors work

Amazon, CVS, Epic and Drugmakers in the News, While Congress Halts Efforts to Repeal and Replace the ACA

IP Blog | Innovation Partners | October 29, 2017

Amazon makes a move to enter the healthcare industry, possibly as a pharmaceutical benefits manager, while Congress shelves plans to repeal and replace the ACA until after the 2018 election. UCLA is under fire for potentially using taxpayer money to create a prostate cancer drug that is being sold at a price tag too high […]

Read Full Post »


prescription pills.

FDA Approves Gilead’s New Treatment for Large B-Cell Lymphoma, Astra and Merck Get Green Light for Fast Review of Lynparza, and More on This Week’s Innovation Partners BioBlog

IP Blog | Innovation Partners | October 22, 2017

This week there’s breakthrough news emerging in the treatment of cancer. The FDA approved Gilead (Kite Pharma’s) gene-therapy treatment for large B-cell lymphoma, offering hope to many patients who didn’t respond well to other treatments. The “cascade of costs” associated with gene therapy, including treatment for side effects, is one factor pushing the price tag […]

Read Full Post »


BioBlog-10-15-image

Cancer Treatment News, Updates on Laws Impacting Healthcare and Insurance Costs and More in This Week’s BioBlog

IP Blog | Innovation Partners | October 15, 2017

In this week’s Innovation Partners BioBlog, cancer is once again in the news, from an increase in obesity and overweight-related cancer diagnosis to drug companies voluntarily lowering chemotherapy drug costs in Africa. President Trump may issue an executive order to undermine portions of the ACA while Iowa is already taking steps in that direction. A […]

Read Full Post »


hepatitis-c-test

New Money Flows into Oncology Sector and More in this Week’s BioBlog

IP Blog | Innovation Partners | October 8, 2017

Oncology treatment and outcomes are front and center this week in the Innovation Partners BioBlog. KSQ Therapeutics is better on CRISPR technology to improve drug development, while Cullinan Oncology takes a funding-based approach to drug development. Other news this week includes the unveiling of a new FDA reporting dashboard, ASCO Advocacy Summit and report from […]

Read Full Post »


The Impact of Medicaid Expansion Under the ACA and the Impact of Changes to 340B, Costs of Services and Pharmaceuticals and More Under Scrutiny.

IP Blog | Innovation Partners | October 1, 2017

This week’s Bio Blog examines the impact of decisions – decisions made by lawmakers, lobbyists, and others as they try to create systems that support healthcare. Medicaid expansion under the ACA is under scrutiny, as are contributions made by pharmaceuticals PACS in 2017. An oncologist penned an insightful essay on the impact of changes to […]

Read Full Post »


BioBlog Weekly image September 24 Innovation Partners

Cost of Prescription Drugs Skyrocketing, Breast Cancer Patients Struggling to Pay for Care, and a New Flurry of Republican-Led Activity to Repeal the ACA in this Week’s Bio Blog

IP Blog | Innovation Partners | September 24, 2017

This week in the Innovation Partners Bio Blog, the attention is on costs – the costs of healthcare premiums, prescription drugs, breast cancer treatments, and more. And while the public’s attention is focused on the rising costs, a Republican-led delegation is once again urging for the repeal of the Affordable Care Act. Last-Ditch Effort By […]

Read Full Post »


Healthcare Marketplace Access News Innovation Partners

Shifting Pharmaceutical Patents to Native American Tribes to Protect Intellectual Property, Shattering the Myth of the Cost of Cancer Drug Development, and More on the Innovation Partners Bio Blog

IP Blog | Dave Melin | September 17, 2017

This week on the Bio Blog, the cost of drugs, especially cancer drugs, is in the spotlight. New evidence indicates that it costs millions, not billions, to produce new cancer medications. California is taking aim at the cost of prescription medicines through the passage of Senate Bill 17 on Monday which will give insurers the […]

Read Full Post »


The Costs of Medications, Updated ESMO Guidelines, and More in This Week’s BioBlog

IP Blog | Dave Melin | September 10, 2017

This week on the Bio Blog, the discussion continues around the cost of medications. U.S. employers seek more narrow insurance benefit designs for employees, and the FDA approved Pfizer’s Mylotarg after a seven-year hiatus. A new app offers data-based symptom tracking for chemotherapy patients, and doctors react to the Trump Administration’s controversial decision to rescind […]

Read Full Post »


BioBlog Weekly oncology

FDA in the News This Week with Changes to Disclosure, Raids and Warnings for Unapproved Stem Cell Treatments

IP Blog | Dave Melin | September 3, 2017

This week on the Bio Blog, the FDA features prominently in the headlines as Commissioner Scott Gottlieb weighs the pros and cons of shorter drug side effect disclosures and leads the charge to protect consumers against unapproved stem cell treatments. A look at this plus the acquisition of Kite Pharma by Gilead and more. What […]

Read Full Post »


IP-logo sq

Pharmaceutical Spotlight: Drug Costs, New Profit/Aging Drugs, Program 340B & More

IP Blog | Dave Melin | August 27, 2017

This week on the BioBlog, we’re taking a closer look at the pharmaceutical industry. Roche is tweaking an aging cancer drug and marketing its replica for MS, demonstrating how profits can be generated from existing medications. Dr. June, the pioneer of immunotherapy, is featured in another article as his treatment developed from research with HIV […]

Read Full Post »


Too Few Patients For Some Drug Trials & Biotech Companies Look at ‘Organs on a Chip’,

IP Blog | Dave Melin | August 21, 2017

This week’s Bio Blog examines several challenges as well as opportunities for biotech and pharmaceutical companies. Although immune therapy and personalized medicine offer many advances in cancer treatment, a lack of suitable patients to test these therapies on may hinder the launch of new drugs. Biotech companies are looking into “organs on a chip”, tissue […]

Read Full Post »


ACA Repeal, Replace or Repairs…is ACA Reform Dead for Now?

IP Blog | Dave Melin | August 13, 2017

This week’s Bioblog focuses on the broader opioid epidemic and concerns over rising incidence of opioid utilization to control cancer pain. President Trump has signified that he will use his bully pulpit to push for new opioid controls and policy changes. Other articles this week include an update and analysis of the Affordable Care Act […]

Read Full Post »


Bio-Blog August 8th, Biopharm news

ACA Repeal Falls Short, Skyrocketing Drug Prices, & A New Digital Health Innovation Action Plan From The FDA

IP Blog | Dave Melin | August 6, 2017

This week’s BioBlog explores many topics related to the biopharmaceutical industry and the Affordable Care Act. Articles on 340B program, the approval of Celgene and Agios’ enasidenib (AG-221), the rising costs of drugs, and other issues directly impacting healthcare throughout America demonstrate the continued need for reform and innovation in the broader healthcare industry. ASCO […]

Read Full Post »


BioBlog Weekly oncology

Obamacare Repeal Failure and Cancer Research Developments

IP Blog | Dave Melin | July 30, 2017

In this week’s BioBlog we look at the failure of the senate to pass a healthcare bill to repeal Obamacare and what it means for insurers and the market. We also look at new developments in cancer research in cancer gene mapping and stem cell therapy. Repeal is Dead (for Now). But Will Obamacare Survive? A […]

Read Full Post »


BioBlog Weekly oncology

New Drugs and Treatments for Leukemia, Alzheimer’s, and Hemophilia

IP Blog | Dave Melin | July 23, 2017

In this week’s BioBlog we learn about new drugs and treatments for leukemia, Alzheimer’s disease, and hemophilia. We also look at a new way the Mayo Clinic is using artificial intelligence to look for potential new drug application, along with Alaska receiving approval for a plan to help stabilize the ACA marketplace in the state. […]

Read Full Post »


BioBlog Weekly oncology

Cancer Drug Research and Pricing and More

IP Blog | Dave Melin | July 16, 2017

In this week’s BioBlog we look at recent happenings in the development and research of cancer drugs, cancer drug price increases, a push by democrats for single-payer healthcare, new Alzheimer disease research, and the ongoing opioid prescription crisis in the US. Lung, Liver and Stomach Cancers Kill a Million Chinese a Year; Big Pharma Responds […]

Read Full Post »


BioBlog Weekly oncology

Exciting New Research and Treatments for Leukemia

IP Blog | Dave Melin | July 9, 2017

In this week’s BioBlog we look into several new studies for Acute Myeloid Leukemia, along with promising new drugs to help treat and reduce relapse occurrence in AML patients. Stem-Cell Researchers Solve Mystery of Relapse in Acute Myeloid Leukemia Scientists have identified a specific type of stem-cell that is present at the time of diagnosis […]

Read Full Post »


BioBlog Weekly oncology

Drug Pricing, MACRA Exemptions, Healthcare Exchange Profitability, and Artificial Intelligence in Healthcare

IP Blog | Dave Melin | July 2, 2017

In this week’s BioBlog we look at the latest developments in the ongoing drug pricing battle, another group of providers receiving exemption from the MACRA requirements, and look into the future of using artificial intelligence in healthcare. Draft Order on Drug Prices Proposes Easing Regulations The New York Times reports that a draft of an […]

Read Full Post »